Impact ledger
Novartis AG (NVS): the developments shaping its investment case
Follow the evidence affecting Novartis AG. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Novartis AG · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-01
Novartis Remibrutinib Meets Primary Endpoint in Phase III MS Trial
Channel: Successful Phase III trial for a novel drug in a significant market (MS) increases future revenue potential and strengthens pipeline. Reduces R&D risk.
Bullish· 1-5y
2026-09-01
Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis
Channel: Successful Phase III trial for a novel drug in a significant market (MS) strengthens future revenue streams and pipeline value.
Bullish· 1-5y
2026-09-05 · 2 reports
Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
Channel: Direct R&D failure, loss of potential future revenue stream from a key pipeline asset.
Bearish· 1-3m
Event impact log
16 events mapped to NVS since 2026-09-01. Evidence through 2026-09-24.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-24 | Kyverna Therapeutics Reports Positive One-Year Data for Miv-cel; Rolling BLA Submission on Track for Q4 2026 | Potential competitive pressure or validation of the CAR T cell therapy approach in autoimmune diseases. Novartis is a leader in CAR T therapies. | watch | 3-12m | 0.20 |
| 2026-09-16 | CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth | Direct revenue growth from increased adoption and market expansion of existing CAR-T therapies (Kymriah) in hematologic oncology. | Bullish | 1-5y | 0.60 |
| 2026-09-14 | FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy | Increased competition in the Spinal Muscular Atrophy (SMA) market, potential erosion of market share for Zolgensma. | Bearish | 3-12m | 0.50 |
| 2026-09-14 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA | Increased competition in the Spinal Muscular Atrophy (SMA) market. Similar to Biogen, Novartis's SMA treatment may face altered market dynamics due to a new combination therapy option. | mixed | 3-12m | 0.30 |
| 2026-09-13 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted SMA Therapy | Increased competition in the Spinal Muscular Atrophy (SMA) market, potentially impacting market share and pricing power for existing therapies. | mixed | 3-12m | 0.30 |
| 2026-09-13 | FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy | Potential competitive pressure or market expansion in the SMA treatment landscape. | watch | 3-12m | 0.30 |
| 2026-09-12 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA | Increased competition in the SMA treatment market, potential for market share shift or pricing pressure. | watch | 3-12m | 0.30 |
| 2026-09-12 | FDA Approves Isembyld for Spinal Muscular Atrophy | Increased competition in the SMA treatment market, potential erosion of market share for existing gene therapies. | Bearish | 1-3m | 0.40 |
| 2026-09-12 | FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy | Increased competition in the Spinal Muscular Atrophy (SMA) treatment market. | Bearish | 1-3m | 0.40 |
| 2026-09-12 | FDA approves Scholar Rock's Isembyld for spinal muscular atrophy | Increased competition in the Spinal Muscular Atrophy (SMA) market, potentially impacting market share and pricing power for existing therapies. | mixed | 3-12m | 0.30 |
| 2026-09-05 | Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint | Direct R&D failure, loss of potential future revenue stream from a key pipeline asset. | Bearish | 1-3m | 0.80 |
| 2026-09-05 | Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M | Direct pipeline failure, loss of future revenue potential from a key drug candidate. | Bearish | 1-3m | 0.70 |
| 2026-09-05 | Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint | Direct R&D failure, loss of potential future revenue stream, increased R&D write-offs. | Bearish | 1-3m | 0.80 |
| 2026-09-01 | Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials | Direct product pipeline success, potential for new revenue stream and market share gain in MS. | Bullish | 1-5y | 0.80 |
| 2026-09-01 | Novartis Remibrutinib Meets Primary Endpoint in Phase III MS Trial | Successful Phase III trial for a novel drug in a significant market (MS) increases future revenue potential and strengthens pipeline. Reduces R&D risk. | Bullish | 1-5y | 0.90 |
| 2026-09-01 | Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis | Successful Phase III trial for a novel drug in a significant market (MS) strengthens future revenue streams and pipeline value. | Bullish | 1-5y | 0.85 |
Continue this research
Build your Novartis AG investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the NVS entity page →